S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
1907, 1929, 1998, 2007--and now 2023? (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
Buy THIS stock before Taiwan is attacked (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
1907, 1929, 1998, 2007--and now 2023? (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
Buy THIS stock before Taiwan is attacked (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
1907, 1929, 1998, 2007--and now 2023? (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
Buy THIS stock before Taiwan is attacked (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
1907, 1929, 1998, 2007--and now 2023? (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
Buy THIS stock before Taiwan is attacked (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
NASDAQ:LIFE

aTyr Pharma (LIFE) Stock Forecast, Price & News

$1.58
-0.01 (-0.63%)
(As of 09/29/2023 ET)
Compare
Today's Range
$1.58
$1.62
50-Day Range
$1.55
$2.01
52-Week Range
$1.53
$3.07
Volume
98,578 shs
Average Volume
183,907 shs
Market Capitalization
$90.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.75

aTyr Pharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
1,213.3% Upside
$20.75 Price Target
Short Interest
Healthy
0.72% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.61mentions of aTyr Pharma in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.01) to ($1.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

278th out of 970 stocks

Biological Products, Except Diagnostic Industry

44th out of 157 stocks


LIFE stock logo

About aTyr Pharma (NASDAQ:LIFE) Stock

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

LIFE Price History

LIFE Stock News Headlines

aTyr Pharma (LIFE) Gets a Buy from Piper Sandler
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Reviewing AlloVir (NASDAQ:ALVR) and aTyr Pharma (NASDAQ:LIFE)
aTyr Pharma (NASDAQ:LIFE) Stock Rating Reaffirmed by HC Wainwright
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
JonesTrading Sticks to Its Buy Rating for aTyr Pharma (LIFE)
The Latest Analyst Ratings for aTyr Pharma
H.C. Wainwright Sticks to Their Buy Rating for aTyr Pharma (LIFE)
See More Headlines
Receive LIFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.

LIFE Company Calendar

Last Earnings
8/09/2023
Today
9/30/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:LIFE
CUSIP
53217V10
Employees
65
Year Founded
2005

Price Target and Rating

Average Stock Price Forecast
$20.75
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+1,213.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-45,340,000.00
Pretax Margin
-433.87%

Debt

Sales & Book Value

Annual Sales
$10.39 million
Book Value
$2.42 per share

Miscellaneous

Free Float
55,255,000
Market Cap
$90.14 million
Optionable
Optionable
Beta
1.26

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Sanjay S. Shukla M.D. (Age 51)
    M.S., Pres, CEO & Director
    Comp: $795.48k
  • Ms. Jill M. BroadfootMs. Jill M. Broadfoot (Age 61)
    Chief Financial Officer
    Comp: $556.62k
  • Ms. Nancy E. Denyes Krueger (Age 55)
    Gen. Counsel & Corp. Sec.
    Comp: $532.13k
  • Xiang-Lei Yang Ph.D.
    Founder
  • Ms. Ashlee Dunston
    Director of Investor Relations & Corp. Communications
  • Mr. Peter Villiger
    VP of Corp. Devel.
  • Ms. Danielle Campbell
    VP of Human Resource
  • Dr. Leslie Nangle Ph.D.
    VP of Research
  • Dr. Ying J. Buechler Ph.D.
    Exec. Director of Biologics Devel. & Manufacturing
  • Dr. David J. King (Age 64)
    Scientific Consultant













LIFE Stock - Frequently Asked Questions

Should I buy or sell aTyr Pharma stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LIFE shares.
View LIFE analyst ratings
or view top-rated stocks.

What is aTyr Pharma's stock price forecast for 2023?

6 Wall Street research analysts have issued 1 year price objectives for aTyr Pharma's shares. Their LIFE share price forecasts range from $9.00 to $35.00. On average, they predict the company's stock price to reach $20.75 in the next twelve months. This suggests a possible upside of 1,213.3% from the stock's current price.
View analysts price targets for LIFE
or view top-rated stocks among Wall Street analysts.

How have LIFE shares performed in 2023?

aTyr Pharma's stock was trading at $2.19 at the beginning of 2023. Since then, LIFE shares have decreased by 27.9% and is now trading at $1.58.
View the best growth stocks for 2023 here
.

Are investors shorting aTyr Pharma?

aTyr Pharma saw a decrease in short interest in September. As of September 15th, there was short interest totaling 411,800 shares, a decrease of 5.9% from the August 31st total of 437,400 shares. Based on an average daily trading volume, of 256,600 shares, the short-interest ratio is presently 1.6 days.
View aTyr Pharma's Short Interest
.

When is aTyr Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our LIFE earnings forecast
.

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) announced its quarterly earnings results on Wednesday, August, 9th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.05.

When did aTyr Pharma's stock split?

aTyr Pharma's stock reverse split before market open on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO?

3 employees have rated aTyr Pharma Chief Executive Officer Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among the company's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

How do I buy shares of aTyr Pharma?

Shares of LIFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is aTyr Pharma's stock price today?

One share of LIFE stock can currently be purchased for approximately $1.58.

How much money does aTyr Pharma make?

aTyr Pharma (NASDAQ:LIFE) has a market capitalization of $90.14 million and generates $10.39 million in revenue each year. The biotechnology company earns $-45,340,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis.

How can I contact aTyr Pharma?

aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The official website for the company is www.atyrpharma.com. The biotechnology company can be reached via phone at (858) 731-8389, via email at investorrelations@atyrpharma.com, or via fax at 858-731-8394.

This page (NASDAQ:LIFE) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -